UBS Upgrades Crucell NV (CRXL) to Buy
More News related to CRXL
- 2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer
- Crucell launches global brand to reflect and reinforce its leading position in healthcare innovation
- TapImmune (TPIV) In License Agreement with Crucell (CRXL)
- UBS Upgrades Crucell NV (CRXL) to Buy
- Crucell NV (CRXL) Posts Q3 EPS of €$0.15, In-Line with Street; Reiterates Guidance
More News related to Upgrades
- RW Baird Makes Positive Comments on Incyte (INCY) Following Novartis Deal
- Incyte (INCY) Strikes Major Drug Development Deal with Noavartis
- Human Genome Sciences (HGSI) Submits BLA to U.S. FDA for Hep C Treatment ZALBIN
- Incyte (INCY) In License Agreement With Novartis, Worth Up to $1 Billion
UBS upgrades Crucell NV (Nasdaq: CRXL) from Neutral to Buy.
To see more analyst ratings on CRXL Click Here.
Related Categories
UpgradesStocks Mentioned
+0.39Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
